# Ouro Medicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ouro-medicines

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.ouromedicines.com
- Total disclosed funding: $120M
- Latest round: Series A (Jan 10, 2025)
- Investors on record: 8

## About

Founded in 2025 and based in California, US, Ouro Medicines, Inc. specializes in creating therapeutics for immune-mediated diseases. In March 2026, Gilead Sciences, Inc. a portfolio company of Third Rock Ventures, Casdin Capital, and Cormorant Asset Management agreed to fully acquire Ouro Medicines, Inc. from UPMC Enterprises, LongRiver Investments, Monograph Capital, Boyu Capital, GlaxoSmithKline, Norwest Venture Partners, TPG, and New Enterprise Associates for an upfront payment of USD 1.68 billion and will receive additional payment of USD 500 million upon achieving milestones.


Ouro Medicines specializes in developing therapeutics aimed at resetting the immune system, focusing primarily on chronic immune-mediated diseases. The company’s core product is the lead therapeutic candidate, OM336, which utilizes T cell engagers (TCEs) to deplete proinflammatory cells. TCEs serve as an off-the-shelf therapeutic modality designed to induce an immunological 'reset,' potentially allowing for durable remissions without ongoing immunosuppression. Additionally, Ouro Medicines is advancing several discovery programs targeting unique subsets of B cells to facilitate longer remissions for certain diseases.

The company operates a revenue model primarily driven by partnerships and collaborations with biopharmaceutical companies for the development and commercialization of its therapeutics. Revenue generation is expected through licensing agreements and milestone payments associated with their lead candidate, OM336, and other products in their pipeline.

The organization plans to use the January 2025 funding for the next phase of its clinical trial in treating immune-mediated diseases.

## Funding rounds

- Series A, Jan 10, 2025, $120M — New Enterprise Associates, TPG, Norwest Venture Partners, GlaxoSmithKline, Boyu Capital, Monograph Capital, LongRiver Investments, UPMC Enterprises

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- TPG (https://capitalatlas.ai/funds/tpg) — Series A
- Norwest Venture Partners (https://capitalatlas.ai/funds/norwest-venture-partners) — Series A
- GlaxoSmithKline — Series A
- Boyu Capital (https://capitalatlas.ai/funds/boyu-capital) — Series A
- Monograph Capital (https://capitalatlas.ai/funds/monograph-capital) — Series A
- LongRiver Investments (https://capitalatlas.ai/funds/longriver-investments) — Series A
- UPMC Enterprises (https://capitalatlas.ai/funds/upmc-enterprises) — Series A